查看文章

This study evaluated the possible protective effects of cilostazol against myonecrosis in dystrophic diaphragm muscle in vivo, focusing on oxidative stress, the inflammatory response and angiogenesis. Young mdx mice, the experimental animal for Duchenne muscular dystrophy, received cilostazol for 14 days. A second group of mdx mice and a control group of C57BL/10 mice received a saline solution. In the mdx mice, cilostazol treatment was associated with reduced loss of muscle strength (−34.4%), decreased myonecrosis, reduced creatine kinase levels (−63.3%) and muscle fibres stained for immunoglobulin G in dystrophic diaphragm muscle (−81.1%), and a reduced inflammatory response, with a decreased inflammatory area (−22%), macrophage infiltration (−44.9%) and nuclear factor‐κB (−24%) and tumour necrosis factor‐α (−48%) content in dystrophic diaphragm muscle. Furthermore, cilostazol …